(Q47957959)

7 February 2018

http://europepmc.org/abstract/MED/24149944

title

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer (English)

1 reference

7 February 2018

http://europepmc.org/abstract/MED/24149944

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

D de Wit

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

H Gelderblom

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

A Sparreboom

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

J den Hartigh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M den Hollander

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

J M C König-Quartel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

T Hessing

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

N P van Erp

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

23 October 2013

1 reference

7 February 2018

http://europepmc.org/abstract/MED/24149944

published in

Cancer Chemotherapy and Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

87-96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24149944%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-013-2322-7

2 June 2020

exact match

0 references

cites work

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Dexamethasone as a probe for vinorelbine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Population pharmacokinetics of weekly docetaxel in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Phenotyping drug disposition in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Mitotane has a strong and a durable inducing effect on CYP3A4 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7

Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2322-7